Answers are grounded in this paper and cite their sources.
Human leukocyte antigen (HLA)-I molecules can present long peptides, yet the mechanisms by which T-cell receptors (TCRs) recognize featured pHLA-I landscapes are unclear. We compared the binding modes of three distinct human TCRs, CA5, SB27, and SB47, complexed with a "super-bulged" viral peptide (LPEPLPQGQLTAY) restricted by HLA-B*35:08. The CA5 and SB27 TCRs engaged HLA-B*35:08 LPEP similarly, straddling the central region of the peptide but making limited contacts with HLA-B*35:08. Remarkably, the CA5 TCR did not contact the α1-helix of HLA-B*35:08. Differences in the CDR3β loop between the CA5 and SB27 TCRs caused altered fine specificities. Surprisingly, the SB47 TCR engaged HLA-B*35:08 LPEP using a completely distinct binding mechanism, namely "bypassing" the bulged peptide and making extensive contacts with the extreme N-terminal end of HLA-B*35:08. This docking footprint included HLA-I residues not observed previously as TCR contact sites. The three TCRs exhibited differing patterns of alloreactivity toward closely related or distinct HLA-I allotypes. Thus, the human T-cell repertoire comprises a range of TCRs that can interact with "bulged" pHLA-I epitopes using unpredictable strategies, including the adoption of atypical footprints on the MHC-I. Background: The mechanisms by which T cell receptors (TCRs) engage lengthy peptides bound to human leukocyte antigens (HLA) is unclear. Results: We have determined the structures of two TCRs binding to a 13-residue bulged peptide presented by HLA-B*35:08. Conclusion: TCRs can adopt markedly differing docking strategies upon engaging lengthy bulged peptides. Significance: The human T-cell repertoire is sufficiently robust to deal with viral determinants of atypical length.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: